Bayer AG sells biologics plant with support of Redeker Sellner Dahs

Bonn, 21 December 2020. The Redeker Sellner Dahs law firm has advised Bayer AG in connection with the sale of a biologics facility to a German subsidiary of WuXi Biologics. Located at the site of the Pharmaceuticals Division in Wuppertal, Germany, the facility is to be sold in a package deal along with a long‑​term lease and services. WuXi Biologics is planning to manufacture active ingredients for COVID‑19 vaccines and other biologics at the facility. Bayer AG will be supporting the new owner with services as the facility is ramped up for the production of vaccine and other biologics.

The volume of the transaction is around EUR 150 million. The deal is expected to close in the first half of 2021 and is subject to review by government agencies.

Under the project management of Dr. Markus Dierksmeier, Bartholomäus Aengenvoort and Alexander Leidig, Redeker Sellner Dahs is once again assisting Bayer AG in a major transaction.

Legal advisors to Bayer AG from Redeker Sellner Dahs

Assisting the project from Bayer AG:

  • Legal: Dr. Claus Moritz Trube (Senior Legal Counsel, Attorney at Law (in‑​house counsel), Law, Patents & Compliance),
  • Labour Law: Dr. Jan Schell (Head of Labor & Social Law, Attorney at Law (in‑​house counsel)).
  • Indirect Taxes: Katrin Berg (Tax Advisor, Group Finance)

Advisor for WuXi Biologics – Heuking Kühn Lüer Wojtek:

  • Dirk W. Kolvenbach, Corporate, Düsseldorf
  • Michael Pauli, LL.M. , Corporate, Cologne
  • Mathis Dick, LL.M. , Real Estate, Düsseldorf
  • Michael Below, Public Law, Düsseldorf
  • Dr. Bodo Dehne, Investment Control, Düsseldorf

your contact

Christiane Legler

Christiane Legler

Willy‑​Brandt‑​Allee 11
53113 Bonn
T +49 228 72625‐472
F +49 228 72625‐99